Trametinib
CAS 871700-17-3
Overview
Trametinib, as monotherapy or in combination with dabrafenib is indicated for the treatment of melanoma and glioma. Trametinib has been used off label to treat various RASopathies, including Noonan Syndrome and Primary Intestinal Lymphangiectasia
Anant Labs manufacture and furnish high quality Trametinib impurities for global markets. Our Trametinib EP Impurities are used by API manufacturers and fully integrated pharmaceutical companies worldwide.
